Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Jun;171(1-2):23-8.
doi: 10.1023/a:1006846501081.

Formation of advanced glycation end (AGE) products in diabetes: prevention by pyruvate and alpha-keto glutarate

Affiliations

Formation of advanced glycation end (AGE) products in diabetes: prevention by pyruvate and alpha-keto glutarate

S D Varma et al. Mol Cell Biochem. 1997 Jun.

Abstract

Glycation of proteins and their subsequent structural and functional modifications have been ascribed to play a prominent role in the pathogenesis of several secondary complications of diabetes, such as cataract and retinopathy. In addition, it plays a role in the generalized ageing process as well. Investigations have been conducted to explore the possibility of preventing the above process by use of pyruvate and alpha-keto glutarate as representatives of physiologically compatible keto acids. The results demonstrate that both these compounds are effective in preventing the initial glycation reaction as well as the formation of AGE products. Both these compounds also inhibit the generation of high molecular weight aggregates associated with cataract formation. Mechanistically, the preventive effects appear to be due to (1) competitive inhibition of glycation by the keto acids and (2) the antioxidant (radical scavenging) properties of these compounds. The results are hence considered useful from the point of view of developing these and other keto acid derivatives as pharmacological agents useful in preventing glycation related protein changes and consequent tissue pathological manifestations.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Invest Ophthalmol Vis Sci. 1982 Feb;22(2):174-9 - PubMed
    1. Biochem Pharmacol. 1993 Oct 5;46(7):1139-44 - PubMed
    1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
    1. Science. 1977 Jan 14;195(4274):205-6 - PubMed
    1. Science. 1975 Jun 20;188(4194):1215-6 - PubMed

Publication types

MeSH terms

LinkOut - more resources